Reports Q4 revenue $8.69M, consensus $7.91M. “We are pleased to report strong financial results in 2024, including a return to core revenue ...

MaxCyte will host a conference call today, March 11, 2025, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived ...

View Our Latest Stock Analysis on MaxCyte MaxCyte Stock Performance MXCT stock opened at $3.06 on Thursday. The stock has a market cap of $324.23 million, a P/E ratio of -9.00 and a beta of 1.35 ...

MaxCyte Inc (NASDAQ:MXCT) reported a strong year in 2024 with a return to core revenue growth and strategic improvements in operations. The acquisition of SecureDX is expected to enhance MaxCyte's ...

ROCKVILLE, MD - MaxCyte, Inc. (NASDAQ:MXCT; LSE:MXCT), a company specializing in cell-engineering technologies for cell-based therapies, has filed its Form 10-K annual report for the fiscal year ...

(Alliance News) - MaxCyte Inc on Tuesday said its annual loss widened amid higher costs and falling revenue, but it remains optimistic about growth prospects for 2025. The Rockville, Maryland ...

ROCKVILLE, MD - MaxCyte, Inc. (NASDAQ:MXCT) reported fourth quarter earnings that beat analyst expectations, but saw revenue plummet 45% YoY, sending shares down 10.4% in after-hours trading.

MaxCyte Inc (MXCT) showcases strong core revenue growth and strategic acquisitions despite facing revenue declines and macroeconomic pressures. ROCKVILLE, Md., March 11, 2025 (GLOBE NEWSWIRE ...

ROCKVILLE, MD - MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a cell-engineering company focused on enabling technologies for cell therapeutics, has reported a mixed financial outcome for the fourth ...

MaxCyte is providing initial 2025 revenue guidance for core business revenue and SPL Program-related revenue: Core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from ...

ROCKVILLE, MD - MaxCyte, Inc. (NASDAQ:MXCT) reported fourth quarter earnings that beat analyst expectations, but saw revenue plummet 45% YoY, sending shares down 10.4% in after-hours trading. The cell ...

MaxCyte expects to end 2025 with $160 million in total cash, cash equivalents and investments. Webcast and Conference Call Details MaxCyte will host a conference call today, March 11, 2025, at 4:30 ...